- Home
- CMTG vs VNDA Comparison
CMTG vs VNDA Comparison
Compare CMTG & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMTG | VNDA |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 256.8M | 301.1M |
| IPO Year | 2016 | 2005 |
Fundamental Metrics
Financial Performance| Metric | CMTG | VNDA |
|---|---|---|
| Price | $1.21 | $4.06 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $2.08 | ★ $11.75 |
| AVG Volume (30 Days) | 777.7K | ★ 826.5K |
| Earning Date | 11-03-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $187,828,000.00 | ★ $216,105,000.00 |
| Revenue This Year | N/A | $15.16 |
| Revenue Next Year | N/A | $35.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $1.09 | $3.97 |
| 52 Week High | $3.62 | $9.91 |
Technical Indicators
Market Signals| Indicator | CMTG | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 43.59 | 26.58 |
| Support Level | N/A | N/A |
| Resistance Level | $1.65 | $5.37 |
| Average True Range (ATR) | 0.06 | 0.18 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 71.88 | 8.82 |
Price Performance
Historical ComparisonAbout CMTG Claros Mortgage Trust Inc.
Claros Mortgage Trust Inc is a real estate investment trust. The company is focused mainly on creating a diversified portfolio of income-producing loans collateralized by institutional-quality commercial real estate.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.